Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

por Wilson, Lisa L., Eans, Shainnel O., Ramadan-Siraj, Insitar, Modica, Maria N., Romeo, Giuseppe, Intagliata, Sebastiano, McLaughlin, Jay P.
Publicado 2022

Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain

por Cirino, Thomas J., Eans, Shainnel O., Medina, Jessica M., Wilson, Lisa L., Mottinelli, Marco, Intagliata, Sebastiano, McCurdy, Christopher R., McLaughlin, Jay P.
Publicado 2019

Development of New Benzylpiperazine Derivatives as σ(1) Receptor Ligands with in Vivo Antinociceptive and Anti-Allodynic Effects

por Romeo, Giuseppe, Bonanno, Federica, Wilson, Lisa L., Arena, Emanuela, Modica, Maria N., Pittalà, Valeria, Salerno, Loredana, Prezzavento, Orazio, McLaughlin, Jay P., Intagliata, Sebastiano
Publicado 2021

Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain

por Wilson, Lisa L., Alleyne, Amy R., Eans, Shainnel O., Cirino, Thomas J., Stacy, Heather M., Mottinelli, Marco, Intagliata, Sebastiano, McCurdy, Christopher R., McLaughlin, Jay P.
Publicado 2022